KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Cash & Equivalents (2016 - 2025)

Fulgent Genetics' Cash & Equivalents history spans 10 years, with the latest figure at $50.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 8.98% year-over-year to $50.2 million; the TTM value through Dec 2025 reached $50.2 million, down 8.98%, while the annual FY2025 figure was $50.2 million, 8.98% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $50.2 million at Fulgent Genetics, down from $117.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $353.1 million in Q1 2022 and bottomed at $5.5 million in Q2 2021.
  • The 5-year median for Cash & Equivalents is $66.2 million (2024), against an average of $89.3 million.
  • The largest annual shift saw Cash & Equivalents soared 6296.51% in 2021 before it crashed 92.4% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $77.1 million in 2021, then grew by 3.16% to $79.5 million in 2022, then increased by 22.6% to $97.5 million in 2023, then tumbled by 43.43% to $55.1 million in 2024, then fell by 8.98% to $50.2 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Cash & Equivalents are $50.2 million (Q4 2025), $117.6 million (Q3 2025), and $87.9 million (Q2 2025).